Oral omecamtiv mecarbil: Additional Phase II data
Additional data from 445 patients with chronic heart failure and left ventricular systolic dysfunction in the double-blind, international Phase II COSMIC-HF trial showed that dose-titrated oral omecamtiv mecarbil significantly improved mean Kansas City Cardiomyopathy Questionnaire (KCCQ) total symptom score from baseline to week 20 vs. placebo (9.9 points vs. 5 points, p=0.03). Patients received placebo, twice-daily 25 mg omecamtiv mecarbil or omecamtiv mecarbil starting at 25 mg with dose escalation to 50 mg twice daily depending on plasma concentrations of the product after 2 weeks of treatment. In moderately to very severely symptomatic patients (n=202), dose-titrated omecamtiv mecarbil reduced mean KCCQ total symptom score from baseline to week 20 by 16 points vs. 9.5 points for placebo (p=0.09). Data were presented at the Heart Failure Society of America meeting in Orlando...